Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a comprehensive portfolio of anti-CCR8 recombinant antibodies, designed to meet the diverse needs of researchers investigating immune function and related diseases. Our precision-engineered products are designed to deliver superior specificity, sensitivity, and reproducibility, ensuring the highest standards of accuracy and reliability in your research endeavors. Whether you're exploring basic immunology or developing novel therapeutic approaches, Creative Biolabs is your trusted partner in CCR8 antibody research.
CCR8, a key receptor involved in Treg recruitment to tumors, plays a crucial role in creating an immunosuppressive environment that shields tumors from immune attack. By inhibiting CCR8 with antibodies, researchers aim to disrupt Treg accumulation, potentially enhancing anti-tumor immune responses and hindering tumor growth. Recent studies have demonstrated the efficacy of anti-CCR8 antibodies in reducing Treg infiltration and their immunosuppressive effects within tumors, suggesting that targeting CCR8 holds significant potential for developing innovative cancer therapies.
CCR-8; Chemokine (C-C motif) receptor 8; C-C chemokine receptor 8; C-C motif chemokine receptor 8; CC-CKR-8; CDw198; CMKBR8; CKRL1; CMKBRL2; TER1; CY6; GPRCY6.
This gene encodes a member of the beta chemokine receptor family, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. Chemokines and their receptors are important for the migration of various cell types into the inflammatory sites. This receptor protein preferentially expresses in the thymus. I-309, thymus activation-regulated cytokine (TARC) and macrophage inflammatory protein-1 beta (MIP-1 beta) have been identified as ligands of this receptor. Studies of this receptor and its ligands suggested its role in regulation of monocyte chemotaxis and thymic cell apoptosis. More specifically, this receptor may contribute to the proper positioning of activated T cells within the antigenic challenge sites and specialized areas of lymphoid tissues. This gene is located at the chemokine receptor gene cluster region.
CD markers, G-protein coupled receptors
Intracellular, Membrane (different isoforms)
Cell type enhanced (T-cells)
Immune cell enriched (T-reg)
Cell line enriched (HDLM-2)
G-protein coupled receptor, Receptor, Transducer
Creative Biolabs offers a versatile selection of recombinant CCR8 antibodies, engineered in various formats to meet diverse research needs. Our antibodies empower researchers to conduct precise and efficient experiments, advancing your projects with confidence.
Table 1. Featured anti-CCR8 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOB-3049z-F(E) | Recombinant Anti-Human CCR8 Antibody Fab Fragment | Human | Mouse Fab | Radioimmunoassay, Immunofluorescence, Functional Study |
NEUT-274CQ | Rat Anti-CCR8 Recombinant Antibody (clone CBL712) | Human | Rat IgG2b | Neut |
ZG-0139U | Human Anti-CCR8 Recombinant Antibody (clone 2C6) | Human | Human hgG1 | FC |
MOB-3049z | Mouse Anti-CCR8 Recombinant Antibody | Human | Mouse IgG1, κ | FC |
MOB-019CQ | Rabbit Anti-Human CCR8 Antibody | Human | Rabbit IgG | ELISA, WB, IHC |
Creative Biolabs is committed to delivering premium anti-CCR8 recombinant antibodies, engineered for groundbreaking immunological research. Our state-of-the-art laboratories adhere to rigorous quality control protocols to ensure each antibody exhibits exceptional specificity and efficacy. By continuously refining our production techniques, our team of experts ensures that our offerings remain at the forefront of antibody research.
Fig.1 FC analysis of anti-CA9 antibody
(Cat# ZG-0139U, Creative Biolabs).
Our proprietary anti-CCR8 recombinant antibody platform leverages genetically engineered cells to produce high-quality, CCR8-specific antibodies. This cutting-edge system enables scalable and efficient production, guaranteeing a reliable supply for diverse applications.
Featured Anti-CCR8 Recombinant Antibody Production Platforms
Fig.2 Milligram-scale anti-CCR8 recombinant antibody production.
Fig.3 Gram-scale anti-CCR8 recombinant antibody production.
Creative Biolabs provides a comprehensive range of high-quality anti-CCR8 recombinant antibodies, available in diverse formats to accommodate a variety of research applications.
Fig.4 Full-length anti-CCR8 recombinant antibody production and modalities.
Table 2. Public drug targeting CCR8.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Phase I/II | Anti-CCR8 (C-C Chemokine Receptor Type 8) |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer, solid tumor | LaNova Medicines (Originator) |
Preclinical |
Anti-CCR8 (C-C Chemokine Receptor Type 8) Anti-CTLA4 (Cytotoxic T-Lymphocyte Protein 4; CD152) Immune Checkpoint Inhibitors |
Bispecific Antibody Fusions Cancer Immunotherapy Fusion Proteins Monoclonal Antibodies Polypeptides, from 41 AA Single-Chain V-Domain Antibody Fragment (scFv) |
Cancer, colorectal | Mabwell (Shanghai) Bioscience (Originator) |
Preclinical |
Anti-CCR8 (C-C Chemokine Receptor Type 8) Anti-CTLA4 (Cytotoxic T-Lymphocyte Protein 4; CD152) Immune Checkpoint Inhibitors |
Bispecific Antibodies Cancer Immunotherapy |
Cancer, colorectal | Biotheus (Originator) |
Preclinical |
Anti-CCR8 (C-C Chemokine Receptor Type 8) Anti-CTLA4 (Cytotoxic T-Lymphocyte Protein 4; CD152) Immune Checkpoint Inhibitors |
Antibody-Derived Binding Proteins Bispecific Antibody Fusions Cancer Immunotherapy Fc Fusion Proteins Polypeptides, from 41 AA Single-Domain Antibodies |
Cancer | Genor Biopharma (Originator) |
Biological Testing |
Anti-CCR8 (C-C Chemokine Receptor Type 8) Anti-TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily Member 1B; TNFR2) Signal Transduction Modulators |
Bispecific Antibody Fusions Cancer Immunotherapy Human Monoclonal Antibodies Polypeptides, from 41 AA Single-Domain Antibodies |
Cancer | Excel Harvest (China) Biopharmaceutical (Originator) |
Biological Testing |
C-C Chemokine Receptor Type 8 (CCR8) Ligands Drugs Targeting B-Lymphocyte Antigen CD19 Signal Transduction Modulators |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Autoimmune disease Cancer Infections Transplant rejection |
Nanjing Bioheng Biotechnology (Originator) |
Biological Testing |
C-C Chemokine Receptor Type 8 (CCR8) Ligands Drugs Targeting T-Cell Surface Glycoprotein CD3 Signal Transduction Modulators T-Cell Engagers |
Bispecific Antibody Fusions Cancer Immunotherapy Fusion Proteins Polypeptides, from 41 AA Single-Chain V-Domain Antibody Fragment (scFv) |
Cancer, solid tumor | Amgen (Originator) |
Biological Testing | Drugs Targeting Mesothelin |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Cancer | LMU Klinikum (Originator) |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Need a top-notch anti-CCR8 antibody? Creative Biolabs has you covered. Contact us to chat about your research and find the perfect fit.